RecruitingPhase 2NCT05632809

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Sponsor

M.D. Anderson Cancer Center

Enrollment

39 participants

Start Date

Jan 10, 2023

Study Type

INTERVENTIONAL

Conditions

Lung Cancer

Summary

To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a drug called NKTR-255 to see if it can help rebuild the immune system of people with non-small cell lung cancer (NSCLC) after they receive chemoradiotherapy, which often weakens the immune system significantly. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with non-small cell lung cancer - You are receiving cancer treatment with curative intent (not just palliative) - You do not have other concurrent cancers (with some exceptions) **You may NOT be eligible if...** - You are receiving treatment only for symptom management, not cure - You have another active cancer at a different site - You did not provide written consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.